Kristi Rosa

Associate Editorial Director, OncLive®
Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. She helped launch the rapidly growing infectious disease news resource Contagion, strengthened the Rare Disease Report, of HCPLive, and now oversees OncLive and its flagship publication OncologyLive. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com

Articles

Genetic Testing Grows as Critical Component in NSCLC Treatment

October 1st 2019

Alberto Chiappori, MD, discusses emerging biomarkers in non–small cell lung cancer and the different ways to test for them.

POLO Trial Underscores Need for Screening in Metastatic Pancreatic Cancer

September 27th 2019

Donald A. Richards, MD, PhD, highlights the key takeaways from the pivotal POLO trial and underscores the importance of genetic testing in metastatic pancreatic cancer.

Afatinib Generates Excitement in NRG1 Fusion+ Lung Cancer, But Challenges Remain

September 24th 2019

Early data suggest that afatinib (Gilotrif) is a potentially effective treatment option for patients with lung adenocarcinoma who have NRG1 fusions, but the identification of these fusions continues to pose a challenge.

NYU Langone's Perlmutter Cancer Center Buzzing With Breast Cancer Research

September 23rd 2019

Thought leaders from NYU Langone’s Perlmutter Cancer Center highlight the latest groundbreaking breast cancer research being conducted at their institution.

Brentuximab Vedotin and Nivolumab Explored in Frontline Hodgkin Lymphoma Regimen

September 23rd 2019

The addition of the antibody-drug conjugate brentuximab vedotin and the PD-1 inhibitor nivolumab to chemotherapy in patients with stage I/II Hodgkin lymphoma is under investigation in an ongoing phase II trial (NCT03233347).

Research Flourishes in Hematologic Malignancies at City of Hope

September 5th 2019

Experts from City of Hope share insight on some of the pivotal research being conducted at their institution.

Novel Immunotherapy Combos Shake Up Bladder Cancer Paradigm

September 4th 2019

Petros Grivas, MD, highlights the evolving role of immunotherapy in bladder cancer and ongoing research slated to further progress along.

TIL Therapy LN-145 Produces Promising Responses in Recurrent, Metastatic, and Persistent Cervical Cancer

August 31st 2019

The tumor-infiltrating lymphocyte therapy LN-145 induced promising response rates with acceptable safety in patients with recurrent, metastatic, or persistent cervical cancer—a patient population of great unmet need.

Neoadjuvant Chemo Safer Alternative for Certain Patients With Ovarian Cancer

August 29th 2019

Linda R. Duska, MD, discusses the ongoing debate between upfront surgery and neoadjuvant chemotherapy in ovarian cancer and the data that support both options.

Frontline Nivolumab/Ipilimumab Combo Shows Robust Activity in MSI-H/dMMR mCRC

August 23rd 2019

The frontline combination of nivolumab (Opdivo) and ipilimumab (Yervoy) showed a robust and durable clinical benefit in patients with metastatic colorectal cancer.

Ovarian Cancer Researchers Continue to Push the Envelope

August 21st 2019

At the 2019 OncLive® State of the Science Summit™ on Ovarian Cancer, we asked experts from the University of Pittsburgh Medical Center about the intriguing research being conducted at their institution.

Questions Remain Across Treatment Modalities in Ovarian Cancer

August 20th 2019

John Comerci, Jr, MD, provides an overview of advances made in ovarian cancer and remaining challenges to address with future research.

PARP Inhibition Improves PFS as Frontline Maintenance in Ovarian Cancer, OS Data Awaited

August 20th 2019

Lan G. Coffman, MD, PhD, discusses pivotal trials evaluating frontline maintenance therapy in advanced ovarian cancer and unanswered questions that still need to be addressed with future research.

Preventing Progression and Chasing Cure in Smoldering Myeloma

August 14th 2019

Data from several clinical trials support treatment with lenalidomide (Revlimid) plus low-dose dexamethasone in select patients with high-risk smoldering multiple myeloma to prevent disease progression and other promising combinations under investigation are showing curative potential.

Combinations Mark Future of Immunotherapy in Multiple Myeloma

August 14th 2019

The emergence of monoclonal antibodies, immunomodulatory agents, immunotoxins, bispecific T-cell engagers, and CAR T-cell therapies will redefine multiple myeloma treatment. However, these new approaches, by themselves, are not enough to achieve cure; they must be used in combination.

Novel Induction Regimens Boost Survival in Newly Diagnosed Myeloma

August 13th 2019

The goal of induction regimens for patients with newly diagnosed multiple myeloma is to reduce the burden of disease and prolong durability of response and overall survival, while minimizing toxicity.

Rapid Advances in ALK+ and ROS1+ NSCLC Bring Forth New Challenges

August 13th 2019

Conor E. Steuer, MD, discusses emerging agents in the treatment of patients with ALK- or ROS1-positive non–small cell lung cancer and the sequencing challenges that have resulted in the space.

Top Breast Cancer Oncologists Highlight Their Ongoing Research

August 8th 2019

Experts from Emory University School of Medicine, Massachusetts General Hospital, and Hospital of the University of Pennsylvania, highlight the exciting research being conducted at their respective institutions.

Novel Approaches Make Headway in HER2+ Metastatic Breast Cancer

August 1st 2019

Manali Bhave, MD, highlights the novel agents under investigation in the treatment of patients with metastatic HER2-positive breast cancer.

Afatinib Shows Potential in NRG1-Positive Gastrointestinal Cancers

August 1st 2019

Benjamin Weinberg, MD, provides insight into NRG1 fusions, the effectiveness of afatinib in patients harboring these fusions, and future research being done in NRG1 fusion–positive gastrointestinal cancers.